| 0.54 0.049 (9.98%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.79  |
1-year : | 0.94 |
| Resists | First : | 0.67 |
Second : | 0.8 |
| Pivot price | 0.53 |
|||
| Supports | First : | 0.46 | Second : | 0.39 |
| MAs | MA(5) : | 0.5 | MA(20) : | 0.56 |
| MA(100) : | 0.59 |
MA(250) : | 1.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21 |
D(3) : | 12.6 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 4.69 | Low : | 0.39 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ASLN ] has closed below upper band by 49.4%. Bollinger Bands are 68.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.48 - 0.49 | 0.49 - 0.49 |
| Close: | 0.53 - 0.54 | 0.54 - 0.55 |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Tue, 16 Apr 2024
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now - Yahoo Lifestyle Australia
Tue, 16 Apr 2024
ASLAN Pharmaceuticals' (ASLN) Buy Rating Reaffirmed at HC Wainwright - Defense World
Fri, 12 Apr 2024
Aslan Pharmaceuticals Launches $12M ADS Offering - TipRanks.com - TipRanks
Fri, 12 Apr 2024
ASLAN Pharmaceuticals Advances Clinical Trials - TipRanks.com - TipRanks
Tue, 09 Apr 2024
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year? - Yahoo Finance
Wed, 13 Mar 2024
Aslan Pharma stock target cut to $10 on financing dilution - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 372 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 117 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.77 |
| Profit Margin | 0 % |
| Operating Margin | -364.5 % |
| Return on Assets (ttm) | -63.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.53 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | -0.71 |
| Price to Sales | 1.01 |
| Price to Cash Flow | -0.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|